A combination of durvalumab and chemotherapy was found to improve outcomes for patients with muscle-invasive bladder cancer compared to neoadjuvant chemotherapy alone. Durvalumab, a monoclonal antibody that binds to PD-L1, has been approved for various oncology indications. The phase 3 NIAGARA trial included over 1,000 patients with muscle-invasive bladder cancer and showed improvements in event-free survival (EFS) and overall survival (OS) with the addition of durvalumab to chemotherapy before surgery. The combination did not lead to increased adverse events or therapy discontinuation rates. Complete data from the trial will be presented at a medical conference.
Source link
Durvalumab regimen improves survival in muscle-invasive bladder cancer
